Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

November 2007, Regeneron Pharmaceuticals ($REGN @Regneron) entered into a global, strategic collaboration with Sanofi ($SNY @Sanofi) to discover, develop, and commercialize fully human monoclonal antibodies (the “Antibody Collaboration”). The Antibody Collaboration is governed by the companies’ Discovery and Preclinical Development Agreement (“Antibody Discovery Agreement”) and a License and Collaboration Agreement. Upfront Payment $85MM for Regeneron […]

May 2013 Array BioPharma (ARRY) entered into a Development and Commercialization Agreement with Oncothyreon (ONTY) to collaborate on development and commercialization of ONT380 for the treatment of cancer (previously known also as ARRY380). Upfront Payment Oncothyreon paid Array a onetime fee of $10MM This agreement was terminated effective December 11, 2014. December 2014, Array BioPharma […]

April 2010, Array BioPharma (ARRY) entered into a license agreement with Novartis (NVS) @Novartis which granted Novartis the exclusive worldwide right to develop and commercialize binimetinib, as well as other specified MEK inhibitors. March 2015, Array regained these rights and the 2010 License Agreement terminated on the Effective Date of the Binimetinib Agreement. January 2015, […]

November 2013, Clovis Oncology ($CLVS @ClovisOncology) acquired Ethical Oncology Science, S.p.A. (“EOS”) (known as Clovis Oncology Italy S.r.l., or “COI”) through which the rights to lucitanib were obtained. 2008, EOS had in-licensed exclusive development and commercial rights to lucitanib on a global basis, excluding China, from Advenchen Laboratories. September 2012, EOS entered into a collaboration and license […]

June 2011, Clovis Oncology ($CLVS @ClovisOncology) entered into a license agreement with Pfizer ($PFE @Pfizer) to obtain exclusive global rights to develop and commercialize rucaparib. The rights are exclusive even as to Pfizer and include the right to grant sublicenses. Upfront Payment $7.0MM Milestone 1 $0.4MM, April 2014, for the initiation of ARIEL3 pivotal registration study Milestone 2.0 $88.5MM […]

May 2010, $CLVS entered into an exclusive worldwide license agreement with Avila Therapeutics, Inc. (now Celgene Avilomics Research Inc., part of Celgene Corporation $CELG) to discover, develop and commercialize a covalent inhibitor of mutant forms of the EGFR gene product. As a result of the collaboration contemplated by the agreement, rociletinib was identified as the […]

  

to top of page...